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Abstract The P2X7 receptor (P2X7R) is uniquely asso-
ciated with two distinct cellular responses: activation of a
dye-permeable pathway allowing passage of molecules up
to 900 Da and rapid release of the pro-inflammatory
cytokine, interleukin-1β (IL-1β), from activated macro-
phage. How this dye uptake path forms and whether it is
involved in IL-1β release has not been known. Pannexin-1
is a recently identified protein found to physically associate
with the P2X7R. Inhibition of pannexin-1 does not alter
P2X7R ion channel activation or associated calcium flux
but blocks one component of P2X7R-induced dye uptake
and unmasks a slower, previously undetected, dye uptake
pathway. Inhibition of pannexin-1 blocks P2X7R-mediated
IL-1β release from macrophage as well as release mediated
by other stimuli which couple to activation of capase-1 and
additionally inhibits the release of interleukin-1α, a member
of the IL-1 family whose processing does not require
caspase-1 activation. Thus, pannexin-1 is linked to both
dye uptake and IL-1β release but via distinct mechanisms.
Keywords Caspase-1.Inflammasome.Dyeuptake.
Inflammation.Macrophage
Introduction
The first report of extracellular adenosine triphosphate
(ATP) as a “cell-permeabilizing” agent was in 1975 when
Rozengurt and Heppel [1] found that p-nitrophenyl phos-
phate entered transformed 3T3 cells during a 5-min exposure
to ATP. Then, in 1979 Cockcroft and Gomperts [2]s i m i l a r l y
found that inorganic phosphates rapidly entered mast cells
upon ATP stimulation. Through the 1980s, work by the
groups of Silverstein [3–7], Weisman [8–11], and Wiley
[12–14] provided pharmacological, biophysical, and bio-
chemical characterization of what became known as the P2Z
receptor [15], which was particularly prominent in immune
cells. The most striking cellular feature that clearly separated
P2Z receptor activation from other purine receptors was
the rapid uptake of higher molecular weight molecules (up
to ∼900 Da). This cell permeabilization process was
considered to be due to the opening of a non-selective
“large pore” in contrast to the cationic channels that formed
the P2X receptor subtype [15]. The P2Z receptor in
macrophage and lymphocytes became a potential anti-
inflammatory drug target by the early 1990s with studies
by the groups of Chaplin [16], Gabel [17–19], Di Virgilio
[20–24], and Dubyak [12, 25–29] demonstrating that ATP,
most likely acting on P2Z receptors, was the most potent
physiological stimulus for the rapid release of the pro-
inflammatory cytokine,interleukin-1β (IL-1β), from activated
monocytes and macrophages. Soon after the Glaxo-
Geneva group discovered the molecular identity of the
P2Z receptor as the P2X7 receptor (P2X7R) in 1996/1997
[30, 31], high throughput screening on heterologously
expressed, or endogenous, P2X7 receptors using dye uptake
assays was begun by virtually all Big Pharma companies
[32, 33]. During this first decade of the twenty-first century,
several highly selective and potent P2X7R antagonists have
been discovered and found to be effective in animal models
of neuropathic pain and other inflammatory processes, most
likely through a reduced release of bioactive IL-1β and other
members of the IL-1 family of pro-inflammatory cytokines
(IL-1α and IL-18) [32]. Most recently, AstraZeneca have
reported initial positive results from phase II clinical trials of
their P2X7R antagonist in the treatment of rheumatoid
arthritis [34]. Thus, the practical link between the P2X7R-
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inflammatory processes in regard to drug discovery is clear.
But is there a physiological link, and, if there is, what is
the underlying mechanism by which the dye uptake path
signals to IL-1 processing and release? This is the main
question we will address in this review. We will focus on
results obtained from studies of endogenous P2X7Ri n
monocytes and macrophage and of heterologously expressed
P2X7R in mammalian cells because few, if any, differences
have been found when comparing data obtained from these
systems. Although P2X7R functions in other immune cells
(neutrophils, B and T lymphocytes) are generally similar to
macrophage, there are some distinct differences that may
suggest alternative signaling pathways and/or interacting
protein complexes; these will not be considered here.
P2X7R ion channel and large pore
Evidence for P2X7R ion channel itself as the large pore
Until very recently, most studies of P2X7R-mediated
membrane currents and dye uptake had concluded that the
P2X7R ion channel itself was the large pore. Several lines
of evidence supported this conclusion. Initial electrophys-
iological studies of the membrane current in macrophage
and ion substitution experiments indicated the response
resulted from a non-selective increase to both cations and
anions [3]. A non-selective and simultaneous increase in
permeability to both cations and anions, primarily in the
form of NaCl, would inevitably draw water into the cell,
leading to cell swelling (an often observed sequelae of
P2X7R activation) with transient plasma membrane dis-
ruption allowing passage of molecules and dyes up to
900 Da size. Subsequent ion replacement studies in the
human embryonic kidney 293 cell line (HEK 293)
ectopically expressing P2X7R indicated the ionic current
resulted solely from a cationic (Na
+,K
+,Ca
++) conductance
but that the channel size dilated over several seconds to
minutes (depending on agonist concentration) so that larger
cations were able to pass [35]. An example of this is shown
in Fig. 1a, where the ATP-evoked current in the presence of
the large cation, N-methyl-D-glucamine (NMDG
+,M W
195), is initially outward due to the outward flow of
intracellular Na
+ but gradually becomes inward as NMDG
begins to flow into the cell. Reversal potential measure-
ments made at 2-s intervals show a progressive shift to
more depolarized potentials (Fig. 1b), delineating the
Fig. 1 Evidence for and against
the P2X7R ion channel itself
dilating to form the dye uptake
large pore. a Example of mem-
brane current recorded in
response to P2X7R stimulation
in extracellular solution con-
taining the large cation,
NMDG
+. Initial current is out-
ward because NMDG
+ initially
is impermeable and only intra-
cellular sodium passes outward
but with time current turns
inward due to NMDG
+ entering
the cell. b Example of reversal
potential measurement experi-
ments carried out at 2-s intervals
during application of BzATP as
shown in (a); reversal potential
shifts to positive values which
shows that NMDG
+ is entering
the cell. c, d Examples of the
same experiment but from cell
expressing mutated P2X7R; now
there is no NMDG
+ shift indi-
cating no entry of NMDG
+ into
the cell, but the same mutated
receptor shows enhanced dye
uptake (e). Recording in (a)i s
from Virginio et al. [35] while
results shown in (b)–(e) are
from Jiang et al. [39]
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gradual change in permeability to larger cations is the most
likely explanation for earlier reports of anion flux through
P2X7R channels because reversal potentials measured at
equilibrium conditions could be interpreted as indicating
permeability to anions as well as cations. Parallel experi-
ments measuring dye uptake (YO-PRO-1 fluorescence) or
simultaneous measurements of dye uptake and membrane
currents showed that the kinetics of dye uptake and NMDG
permeability shift were the same [39]. The tight kinetic
correlation between NMDG permeability shift and dye
uptake was observed at all agonist concentrations and thus
provided strong circumstantial evidence that the P2X7R ion
channel dilated over time to allow the passage of larger
cations and cationic dyes such as YO-PRO-1 (MW 629)
and ethidium bromide (MW 394).
Evidence against P2X7R ion channel itself as the large pore
Certain observations were inconsistent with the hypothesis
that the P2X7R ion channel dilates to allow passage of
larger molecules. Firstly, very low concentrations of the
calmodulin inhibitor calmidazolium were shown to inhibit
the P2X7R ion channel by up to 95% yet did not decrease
dye uptake [36]. Secondly, it was not clear how anionic
dyes, such as Lucifer yellow (MW 457), which are well
established as being taken up by cells in response to P2X7R
activation [3, 6, 37, 38], could permeate the cation-selective
channel. Thirdly, specific deletions or mutations in the C-
terminal domain of the P2X7R were made that completely
blocked pore dilatation as measured by NMDG
+ perme-
ability shifts (Fig. 1c, d) yet dye uptake and membrane
currents were both significantly enhanced [39] (Fig. 1e).
Moreover, although significant YO-PRO-1 uptake was
observed in normal extracellular sodium concentrations,
there was no NMDG permeability increase observed, thus
dissociating NMDG permeability changes from dye uptake
[39]. Finally, low micromolar concentrations of the gap
junction blocker carbenoxolone (CBX) markedly inhibited
P2X7R dye uptake without altering membrane currents or
initial calcium flux [40]. These results suggested two other
possibilities: that P2X7R channel activation induces a
distinct signal transduction pathway which leads to dye
uptake [41], or a distinct P2X7R-interacting protein is the
dye uptake pathway [39].
Pannexin-1 mediates rapid dye uptake pathway
We recently identified pannexin-1 (panx1) as a P2X7R-
associated protein which appears to be the large pore or is
responsible for activation of the large pore [40]. Panx1 and
P2X7R co-immunoprecipitated in HEK 293 cells; small
interfering RNA (siRNA) directed against panx1, a panx1-
mimetic inhibitory peptide (
10panx1 peptide), and CBX all
inhibited P2X7R-mediated dye uptake but not membrane
currents or calcium flux in HEK 293 cells and in human
and murine macrophage [40]. Notably, inhibition of panx1
blocked only an initial phase of the P2X7R-induced dye
uptake, revealing a previously undetected slow (panx1-
independent) dye uptake (Fig. 2)[ 42]. The mechanisms
underlying the slow dye uptake, and/or whether it has any
physiological significance, remain to be determined but it
does not appear to be involved in the release of IL-1β (see
below). Interestingly, two earlier studies had suggested the
involvement of MAP kinase (MAPK) signal transduction in
P2X7R-mediated dye uptake in macrophage: in one study
the dye uptake was found to be calcium-dependent and was
not inhibited by very high concentrations (500 μM) of
CBX [41]. It should be noted that all other studies on
P2X7R-mediated dye uptake have found the process to be
calcium-independent [35, 36, 39]. In a separate study, a
MAPK-dependent component of the dye uptake was
independent of P2X7R-mediated IL-1β release [43]. Because
P2X7R-induced panx1-dependent dye uptake is calcium-
independent, CBX-sensitive, and associated with IL-1β
release [39, 40], it is tempting to speculate that the panx1-
independent slow dye uptake may result from the MAPK
signaling cascade described by Jarvis and colleagues
[43].
Pannexins were originally identified in 2003/2004 by
low sequence homology to invertebrate gap junction chan-
nels, the innexins [44-46]. Like innexins and the mammalian
gap junction channels, connexins, the three members of the
pannexin family (panx1, 2, 3) share a similar membrane
topology consisting of four transmembrane domains, short
extracellular segments, and intracellular C and N termini
[44–46]. Pannexins do not show sequence homology to the
large family of connexin proteins, although recent detailed
phylogenetic analysis has convincingly placed innexins,
pannexins, and connexins within the same molecular
superfamily [47]. In situ hybridization and immunohisto-
chemistry at both light and electron microscopy levels show
that panx1 is widely expressed, particularly in immune cells,
endothelia, and epithelia; panx2 is relatively neuronal-
specific, while panx3 shows fairly localized expression to
joints and skin [45, 46, 48]. Gap junctions are composed of
12 connexin proteins via hexameric connexin complexes
(called connexons or hemichannels) on two adjacent cells
coming together to form a junctional channel through which
ions and small molecular weight (up to 1,000 Da) molecules
can pass [47]. Initial studies in which panx1 was over-
expressed in oocytes suggested panx1 could act to form gap
junctions in a manner similar to that known for connexins
[45, 48], but no gap junction formation has been observed
when panx1 is expressed in mammalian cells [40, 49]a n d
Purinergic Signalling (2009) 5:129–137 131the current understanding is that panx1 does not form gap
junctions [49, 50].
When panx1 is ectopically expressed in HEK 293 cells
lacking P2X7R, a low level of constitutive dye uptake
occurs which is not otherwise observed in untransfected or
vector-transfected cells nor in P2X7R-expressing cells in
the absence of ATP [40]. We have also noted a significant
level of constitutive dye uptake in peritoneal macrophage
obtained from P2X7R
−/− mice that is not seen in wild-type
macrophage (unpublished observations). These findings
may suggest that panx1 is normally under negative control
when it is in association with unstimulated P2X7R.
How panx1 mediates dye uptake has not been resolved
although it is currently assumed that panx1 forms a large
conductance hemichannel in the plasma membrane through
which cationic and anionic molecules of up to 800–900 Da
can pass [46, 49, 50]. This hypothesis is largely based on
analogy to gap junction channels rather than to direct
experimental evidence. The main evidence that panx1 acts
as a large conductance hemichannel is that when panx1 is
heterologously expressed (in the absence of P2X7R), a
cation/anion non-selective membrane current can be
recorded [40, 45]. However, there are critical questions
that must be resolved before panx1 can be considered a
plasma membrane hemichannel through which marker dyes
directly pass. (1) Single channel recordings showing large
conductance unitary opening are critically required. We
have consistently failed to record large conductance single
channels from panx1-expressing, or P2X7R/panx1 over-
expressed, mammalian cells; there is one report of large
conductance single channels (>200 pS) being observed in
oocytes over-expressing panx1 [50], but this does not
appear to be a consistent observation. (2) Site-directed
mutagenesis of residues within the panx1 protein that result
in altered voltage dependence, ion permeability, and/or
unitary conductance are required to provide direct demon-
stration that panx1 is, itself, an ion channel. (3) If a large
conductance pannexin channel is activated by P2X7R
Fig. 2 Two phases to P2X7R-
mediated dye uptake revealed by
inhibition of panx1. a Original
traces of typical dye uptake
experiments carried out on HEK
293 cells expressing rat P2X7R;
each trace shows average ±
SEM from 20 to 30 cells; con-
trol fluorescence (in arbitrary
fluorescence units) saturates the
optical system in both examples.
Inhibition of panx1 with CBX or
10panx1-mimetic inhibitory pep-
tide dramatically delays dye up-
take; results detailed in [40, 42]
suggest two independent pro-
cesses. b Distinct roles and
underlying mechanisms for the
two dye uptake processes after
P2X7R activation. Panx1 is
involved in the initial rapid dye
uptake and in IL-1β processing
and release. Mechanisms under-
lying the slow dye uptake and
its physiological significance are
unknown but results from [43]
suggest it may involve MAPK-
dependent pathways. P2X7R
cartoon is represented as a
homotrimer based on studies of
the mammalian P2X1 and P2X2
receptors [71]. Panx1 cartoon is
represented as a plasma mem-
brane hemichannel consisting of
a complex of six subunits,
hypothetically arranged based
on analogy to connexin gap
junction hemichannels
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inhibition in the ATP-induced current in response to P2X7R
stimulation. But, although CBX and
10panx1 inhibitory
peptide completely block the membrane current recorded
when panx1 is ectopically expressed (in the absence of
P2X7R), they have no effect or slightly enhance the
membrane current activated by P2X7R stimulation in cells
expressing both panx1 and P2X7R[ 40]. (4) It remains
unclear whether endogenous panx1 is a plasma membrane
protein or an endoplasmic reticulum (ER) membrane
protein or both. There is evidence that panx1 may be an ER
membrane protein involved in ER calcium regulation [51].
There are currently no studies showing high-resolution
subcellular localization of endogenous panx1 in macrophage
using antibodies that are highly specific for panx1. (5) Can
endogenous panx1-like currents be recorded from macro-
phage? There are no reports of membrane currents recorded
from monocytes or macrophage (or any neuronal or non-
neuronal cell) having properties similar to those observed
w h e np a n x 1i so v e r - e x p r e s s e di nH E K2 9 3o ro t h e r
mammalian cells. Thus, until these questions are answered,
alternative possibilities must be considered, in particular the
possibility that panx1 may recruit, or activate, transporter
proteins which provide the direct route for entry and exit of
dyes and other small molecules.
P2X7R–pannexin-1 and IL-1β processing and release
The release of bioactive pro-inflammatory cytokine IL-1β
by macrophages is an essential element of innate immunity
and is a multi-step process tightly regulated by the activation
of caspase-1 [52]. Initial inflammatory stimuli by bacterial
pathogen-associated molecular pattern (PAMP) molecules,
such as endotoxin challenge, activate the NFκBc a s c a d e
leading to increased protein synthesis, particularly of pro-
IL-1β,a sw e l la sP 2 X 7R and panx1 [40, 52–55], but a
secondary stimulus is required for efficient processing and
release of bioactive IL-1β [16–19, 53]. ATP is a key
secondary stimulus. Activation of P2X7R by the nucleotide
leads to the assembly of a multi-protein complex called the
NLRP3 inflammasome that recruits pro-caspase-1 and
induces its proteolytic activation (Fig. 3)[ 53–55]. Panx1
appears to be a critical component not only in P2X7R-
mediated IL-1β release but also in all caspase-1 associated
signaling through the NLRP3 inflammasome [40, 42, 56].
Fig. 3 Schematic depicting distinct models of the activation of
caspase-1 and IL-1β release induced by P2X7R and panx1 activation.
Toll-like receptor (TLR) activation by bacterial PAMPs activates the
production of pro-IL-1β as well as enhances the expression and
activity of P2X7R and panx1. Under resting conditions, P2X7R may
keep panx1 under negative regulation via direct interaction. High
concentrations of extracellular ATP activates P2X7R ion channel
resulting in a cation permeability (Na
+ influx/K
+ efflux and intracel-
lular Ca
++ rise) and the activation of panx1. Panx1 activation allows a
rapid dye uptake permeabilization pathway and potentially the entry of
either bacterial PAMPs and/or extracellular ATP that will directly
activate NLRP3 (nucleotide-binding domain and leucine-rich repeat
containing a pyrin domain) molecule using the adaptor molecule ASC
(apoptosis-associated speck-like protein containing a CARD). Acti-
vated NLRP3 with ASC aggregates pro-caspase-1 molecules through
the formation of a macromolecular inflammasome complex that
facilitates subsequent pro-caspase-1 activation and pro-IL-1β process-
ing to its bioactive state. NLRP3 inflammasome complex cartoon is
based on studies on the NLRP1 inflammasome and is probably
comprised of five to seven subunits, each subunit consisting of
NLRP3 and ASC with the ability to recruit five to seven pro-caspase-1
molecules [68]. Inflammasome pictorial adapted from Ting et al. [72]
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10panx1
inhibitory peptide all inhibit P2X7R-mediated IL-1β release
from endotoxin-primed macrophage at similar concentrations
to those that inhibit the initial P2X7R-mediated dye uptake
[40]. This strong correlation led to the initial hypothesis that
opening of dye-permeable panx1 hemichannels via P2X7R
activation directly leads to inflammasome assembly and
activation [40]. While this hypothesis cannot yet be ruled out
in the specific case of P2X7R function, it quickly became
apparent that this cannot be a general mechanism by which
panx1 signals to inflammasome activation when it was found
that panx1 inhibition (via CBX, panx1 gene silencing, and
10panx1 inhibitory peptide) also inhibits processing and
release of bioactive IL-1β via routes that are not associated
with dye uptake [42]. For example, nigericin does not evoke
any dye uptake but is well known to activate NLRP3
inflammasome release of IL-1β and maitotoxin evokes only
a panx1-independent slow onset of dye uptake, but in both
cases, panx1 inhibition prevents IL-1β processing and
release [42].
How might panx1 signal to activate the NLRP3
inflammasome in response to P2X7R stimulation, or to
dye uptake independent stimuli? The classic hypothesis for
activation of caspase-1 via the NLRP3 inflammasome is the
K
+ efflux model [17]. This model is based on three main
observations: (a) activation of P2X7Ri nm a c r o p h a g e s
induces K
+ depletion [17, 40, 53, 57] as does stimulation
with nigericin or maitotoxin; (b) activation of caspase-1 by
these stimuli does not occur in high extracellular K
+
solution [40, 57–59]; and (c) the in vitro assembly of the
inflammasome is dependent on K
+ concentrations lower
than 70 mM [58]. Initially, panx1 was expected to be a
conduit for the high K
+ efflux subsequent to P2X7R
activation, but inhibition of panx1 using
10panx1 inhibitory
peptide abolished caspase-1 activation without altering
P2X7R-mediated K
+ efflux [40]. This result implies that
panx1 signals downstream to K
+ efflux and that K
+ efflux is
independent of panx1-mediated macrophage permeabiliza-
tion and dye uptake. It is also possible that the panx1
inhibitory peptide may block downstream panx1 signaling
without altering direct K
+ permeability through panx1
channels. However, panx1 inhibition does not alter mem-
brane currents or calcium influx in response to P2X7R
activation (see above). Taken together, it seems most likely
that K
+ efflux occurs through the P2X7R ion channel itself
and that panx1 acts on the inflammasome downstream of ion
flux. This idea that panx1 is unlikely to be directly involved
with ion flux in macrophage is further supported by a recent
study where inhibition of panx1 by CBX prevented ATP-
mediated IL-1β release from macrophage, as expected, but
did not alter concurrent release of cathepsin B, this latter
process resulting from a Ca
++-dependent exocytosis of
secretory lysosomes [60].
If K
+ efflux is not the link between panx1 and
inflammasome activation, an alternative hypothesis comes
from the group of Nuñez who have suggested that panx1
activation by P2X7R may act to deliver PAMPs directly
into the cytosol where they can then directly bind to
leucine-rich repeats present in Nod-like receptors (i.e.,
NLRP3) to directly activate the inflammasome [61, 62].
This is an attractive idea whereby PAMPs would be not
only responsible for the initial inflammatory stimulus by
activating the TLR–NFκB synthetic pathway but also for
the secondary stimulus leading to processing and release
of IL-1β via panx1-mediated delivery into the cell
interior. This novel hypothesis is based on observations
that cytosolic delivery of the bacterial PAMP lysosomic
muramyl dipeptide (MDP) activated the inflammasome in
a manner similar to P2X7R and that P2X7R activation
induced a panx1-dependent lysosome-to-cytosol transloca-
tion of MDP [61, 62]. However, there are three major
difficulties in this hypothesis as a generalized mechanism
for inflammasome activation. Firstly, it is not clear how a
P2X7R/panx1 permeabilization pore that is presumably
limited to molecules <900 Da can transfer larger PAMPs.
That is, while PAMPs like MDP (MW 492 Da) may be
expected to pass, other PAMPs are too large, particularly
the classically used lipopolysaccharide (LPS) whose active
fragment, lipid A, has a molecular mass of 1,700–1,800 Da
(depending on the number and identity of fatty acid chains
present) [63]. Secondly, most IL-1 cytokine release experi-
ments are performed by initial incubation with LPS or other
PAMPs followed by washing away these PAMPs and
applying ATP to activate P2X7R[ 40, 58, 60]. Therefore,
minimal levels of PAMPs are likely to be present in the
ATP incubation media for delivery into the cell. Thirdly, the
studies using different PAMPs to activate the inflamma-
some [61, 62] have been carried out in the presence of ATP,
thus release of bioactive IL-1β release must be in part—or
in toto—due to P2X7R activation.
A third hypothesis regarding panx1-mediated activation
of the inflammasome is that extracellular ATP activates the
P2X7R, which in turn activates panx1 hemichannel (or
transporter) activity to directly transport ATP into the cell.
Evidence has been presented to suggest panx1 can act as a
conduit for ATP release from erythrocytes [64]. If panx1 is
a conduit for ATP, it must be a conduit for either entry or
exit of ATP depending on the concentration gradient.
Concentrations of ATP required to activate P2X7R (usually
>100 μM) may be higher than free intracellular ATP in
localized regions near the plasma membrane, especially as
the vast majority of intracellular ATP (∼90%) is produced
in, and bound to, mitochondria [65]. Importantly, ATP can
directly activate capase-1 in cell-free systems [66], and
elevations of intracellular ATP levels have been associated
with, and required for, caspase-1 activation and IL-1β
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mediated inflammasome activation although there is cur-
rently no direct or indirect experimental evidence for or
againstthis hypothesis.However,thishypothesisalsocannot
be a generalized mechanism for panx1 involvement in
caspase-1-dependent IL-1β processing and release because
other stimuli, such as nigericin and maitotoxin, that are
equally panx1-dependent, do not require extracellular ATP.
Recent work in our lab suggests panx1 may have a wider
role in pro-inflammatory cytokine release beyond initial
involvement in caspase-1 activation. In an investigation of
the kinetics of action of
10panx1-mimetic inhibitory peptide,
we found that this peptide was able to stop further IL-1β
release from macrophage after caspase-1/inflammasome
activation had already been instigated by P2X7Rs t i m u l a t i o n .
The
10panx1 peptide did not inhibit caspase-1 activity per se
in cell-free assays, so ruling out a direct chemical or
enzymatic interaction with caspase-1. Moreover, inhibition
of panx1 not only inhibited caspase-1-dependent processing
and release of both IL-1β and IL-18 but also IL-1α which
does not directly require caspase-1 inflammasome activation
for its processing [56]. Additionally, a significant practical
finding was that inhibition lasted for >1 h after removal of
the inhibitory peptide, thus indicating tight, long-lasting
binding and/or prolonged inhibition of unknown processes.
In this regard, it is important to note that prolonged
incubation (>2–3h )w i t ht h e
10panx1 inhibitory peptide is
toxic to macrophage [56]. Although the mechanism of
10panx1-mimetic toxicity during prolonged application has
not been investigated, it clearly differs from the rapid (non-
toxic) inhibition of caspase-1 activation that occurs with
brief (<30 min) applications of this inhibitor [40, 42, 56].
These results make it clear that this compound should be
used with caution, and investigators should ensure that
appropriate optimization protocols (concentration and time
dependence) are carried out when employing this inhibitor.
This is particularly true in view of the well-known variability
in potency/purity of commercially synthesized peptides and
proteins.
Concluding remarks
P2X7R activation leads to numerous downstream signaling
events: the most upstream event subsequent to initial ion
channel opening is induction of the large pore/dye uptake
path that occurs approximately 2–3 s after receptor
activation [35]. The most physiologically relevant down-
stream event is the release of the pro-inflammatory group of
IL-1 cytokines, IL-1α, IL-1β, and IL-18; cytokine release
can be measured by ELISA or Western blot techniques
within 5–15 min of receptor activation [60, 69, 70]
although it is likely that release occurs even sooner. Recent
studies summarized in this review have identified panx1 as
a critical component in both these events, but it appears that
the panx1-dependent dye uptake path is not the causative
event underlying cytokine release. Is this dye uptake event
that has been so extensively utilized since the original
studies in the mid-1970s simply a functionally meaningless
by-product of P2X7R–panx1 activation? If so, it has been
an enormously practical by-product by providing a highly
sensitive and selective screening assay that has resulted in
the identification of potent P2X7R antagonists that are now
of promising therapeutic value in the treatment of inflam-
matory diseases [32–34]. Or, if the dye uptake event does
represent a functionally relevant mechanism underlying
P2X7R function, we have still to discover what this is.
Speculative hypotheses have been discussed in this review
and are depicted in Fig. 3. It is likely that some, or all, of
these hypotheses will be revised, discarded, or perhaps even
shown to be valid, but certainly, they provide exciting
impetus for much further exploration of the P2X7R–
pannexin connection.
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